Targeting BRAF for patients with melanoma

British Journal of Cancer

Volumn 104, Issue 3, 2011, Pages 392-398

  Arkenau, H T ^a   Kefford, R ^b   Long, G V ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BRAF; BRAFV600E; melanoma; PI3K AKT mTOR; RAS RAF MEK ERK

Indexed keywords

B RAF KINASE; CARBOPLATIN; CHIR 265; DACARBAZINE; ERLOTINIB; GELDANAMYCIN; GSK 1120212; GSK 2118436; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLX 4032; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 281;

ARTHRALGIA; BLEEDING; BLOOD TOXICITY; CANCER STAGING; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MELANOMA; METASTASIS; MISSENSE MUTATION; MONOTHERAPY; NAUSEA; NEUROPATHY; NONHUMAN; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 79551595779     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6606030     Document Type: Review

References (47)

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001) Prognostic Factors Analysis of 17 600 Melanoma Patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19(16): 3622-3634
2. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15(1): 9-14
3. Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K, Powell MB (2006) Inhibition of phosphatidylinositol-3-kinase and mitogenactivated protein kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 5(5): 1136-1144
4. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F (2003) Mutation in B-Raf in human choroidal melanoma cell lines mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 278: 42409-42418
5. Catalogue of Somatic Mutations in Cancer (COSMIC) website. http://www. sanger.ac.uk/genetics/CGP/cosmic/: Wellcome Trust Sanger Institute Chapman P, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee R, Grippo J, Nolop K, Flaherty K (2009) Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer 7(3): 5 (abstract 6LB)
6. Cheung M, Sharma A, Madhunapantula AV, Robertson G (2008) Akt3 and mutant V600EBRAF cooperate to promote early melanoma development. Cancer Res 68(9): 3429-3439
7. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20): 2135-2147
8. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePhino RA, McMahon M, Bosenberg M (2009) BRAFv600E cooperates with Pten silencing to elicit metastatic melanoma. Nat Genet 41(5): 544-552
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892): 949-954
10. Dhomen N, Marais R (2009) BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin of North Am 23(3): 529-545
11. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, ODwyer PJ, Ratain MJ (2006) Sorafenib in advanced melanoma: a Phase-II randomised dicontiuation trial analysis. Br J Cancer 5(2): 120-130
12. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106(48): 20411-20416
13. Feldman ME, Shokat KM (2011) New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs). Curr Top Microbiol Immunol 347: 241-262
14. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P (2009) Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27: 15s (abstract 9000)
15. Flaherty KT, Lee SJ, Schuchter LM, Flaherty LE, Wright JJ, Leming PD, Flaherty LE, Wright JJ, Leming PD, Kirkwood JM (2010a) Final results of E2603: a double blind, randomized phase-III trial comparing carboplatin/paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 28: 5s (abstract 8511)
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, ODwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010b) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9): 809-819
17. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS (2009) The mitogen activated protein/ extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY- 142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 15(12): 4147-4156
18. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287): 431-435
19. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, ODay S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U (2009) Results of a phase-III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxcel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27(17): 2823-2830
20. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-Dead BRAF and Oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2): 209-221
21. Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Goetz R, Rapp UR (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3(1): 6
22. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298
23. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28: 15s (abstract 8503)
24. Kuwajima A, Iwashita J, Murata J, Abe T (2007) The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of matrigel. Anticancer Res 27(6B): 4163-4169
25. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, Garbe C, Meier FE (2008) Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abbrogates invasive growth of melanoma cells. J Invest Dermatol 128(8): 2013-2023
26. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, Mason G, Magee J, Angel C, Dobrovic A, McArthur GA (2007) Distinct clinical and pathological features are associated with the BRAFT1799A(V600E) mutation in primary melanoma. J Invest Dermatol 127(4): 900-905
27. Long GV, Menzies AM, Nagrial AM, Haydu LL, Hamilton AL, Mann G, Hughes TM, Thompson JF, Scolyer RA, Kefford R (2010) Clinicopathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. J Clin Oncol 28: 15s (abstract 8548)
28. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH (2005) CCI-779 in metastatic melanoma: a phase-II trial of the California Cancer Consortium. Cancer 104: 1045-1048
29. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J Clin Oncol 26(13): 2178-2185
30. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68(12): 4853-4861
31. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS (2010) Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102(12): 1724-1730
32. Platz A, Egyhazi S, Ringborg U, Hansson J (2008) Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 1: 395-405
33. Populo H, Soares P, Rocha AS, Silva P, Lopes JM (2010) Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 20(2): 107-117
34. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287): 427-430
35. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, Young T, Neri G (2006) The cardiofaciocutaneous syndrome. J Med Genet 43: 833-842
36. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R (2010) J Transl Med 8: 67
37. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sauaville EA (2005) Phase-I and pahrmakokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23(17): 3912-3922
38. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129(6): 1500-1503
39. Shinozaki M, Fujimoto A, Morton DL, Hoon DSB (2004) Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas. Clin Cancer Res 10(5): 1753-1755
40. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL (2008) Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7(9): 2876-2883
41. Schwartz GK, Robertson S, Shen A, Wang E, Pace L, Dials HD, Mendelson D, Shannon P, Gordon M (2009) A phase-I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 27: 15s (abstract 3513)
42. Thomas NE (2006) BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 16(2): 97-103
43. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K (2007) Number of Nevi and Early-Life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16(5): 991-997
44. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365(9460): 687-701
45. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS, and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337-341
46. Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, Rittgen W, Hemminki K, Becker JC, Kumar R, Schadendorf D (2007) B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2(2): e236
47. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome Project (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6): 855-867